SEARCH

SEARCH BY CITATION

References

  • 1
    Thompson I, Thrasher JB, Aus G et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007; 177: 21062131
  • 2
    Heidenreich A, Bellmunt J, Bolla M et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011; 59: 6171
  • 3
    Cooperberg MR, Vickers AJ, Broering JM, Carroll PR. Comparative risk-adjusted mortality outcomes following primary surgery, radiation therapy, or androgen deprivation therapy for localized prostate cancer. Cancer 2010; 116: 52265234
  • 4
    Zelefsky MJ, Eastham JA, Cronin AM et al. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol 2010; 28: 15081513
  • 5
    Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010; 28: 11171123
  • 6
    Cookson MS, Aus G, Burnett AL et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007; 177: 540545
  • 7
    Wei JT, Dunn RL, Sandler HM et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 2002; 20: 557566
  • 8
    Wilson LS, Tesoro R, Elkin EP et al. Cumulative cost pattern comparison of prostate cancer treatments. Cancer 2007; 109: 518527
  • 9
    Hayes JH, Ollendorf DA, Pearson SD et al. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA 2010; 304: 23732380
  • 10
    Konski A, Speier W, Hanlon A, Beck JR, Pollack A. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? J Clin Oncol 2007; 25: 36033608
  • 11
    Zelefsky MJ, Yamada Y, Fuks Z et al. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 2008; 71: 10281033
  • 12
    Kuban DA, Tucker SL, Dong L et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008; 70: 6774
  • 13
    Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR. Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer 2008; 112: 307314
  • 14
    Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31: 13411346
  • 15
    Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 2003; 95: 981989
  • 16
    Hu JC, Gu X, Lipsitz SR et al. Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA 2009; 302: 15571564
  • 17
    Stephenson AJ, Scardino PT, Kattan MW et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007; 25: 20352041
  • 18
    Heidenreich A, Richter S, Thuer D, Pfister D. Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy. Eur Urol 2010; 57: 437443
  • 19
    Stephenson AJ, Shariat SF, Zelefsky MJ et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004; 291: 13251332
  • 20
    Eandi JA, Link BA, Nelson RA et al. Robotic assisted laparoscopic salvage prostatectomy for radiation resistant prostate cancer. J Urol 2010; 183: 133137
  • 21
    Trock BJ, Han M, Freedland SJ et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008; 299: 27602769
  • 22
    Gretzer MB, Trock BJ, Han M, Walsh PC. A critical analysis of the interpretation of biochemical failure in surgically treated patients using the American Society for Therapeutic Radiation and Oncology criteria. J Urol 2002; 168: 14191422
  • 23
    Nielsen ME, Makarov DV, Humphreys E, Mangold L, Partin AW, Walsh PC. Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion – ‘nadir + 2'? Urology 2008; 72: 389393
  • 24
    Freedland SJ, Humphreys EB, Mangold LA et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 433439
  • 25
    Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 15911597
  • 26
    Sandler HM, Dunn RL, McLaughlin PW, Hayman JA, Sullivan MA, Taylor JM. Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys 2000; 48: 629633
  • 27
    Arias E. United States life tables, 2004. Natl Vital Stat Rep 2007; 56: 139
  • 28
    Abdel-Wahab M, Reis IM, Hamilton K. Second primary cancer after radiotherapy for prostate cancer–a SEER analysis of brachytherapy versus external beam radiotherapy. Int J Radiat Oncol Biol Phys 2008; 72: 5868
  • 29
    Altekruse SF, Kosary CL, Krapcho M et al. SEER Cancer Statistics Review, 1975–2007. 2010. Available at: http://seer.cancer.gov/csr/1975_2007/. Accessed September 2012
  • 30
    Bechis SK, Carroll PR, Cooperberg MR. Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol 2011; 29: 235241
  • 31
    Wennberg JE , ed. The quality of medical care in the United States: a report on the Medicare program. Chicago, IL: Health Forum, Inc., 1999, pp. 1313
  • 32
    Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst 2006; 98: 839845
  • 33
    Bill-Axelson A, Holmberg L, Filen F et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008; 100: 11441154
  • 34
    Wilt TJ, Brawer MK, Jones KM et al. Radical prostatectomy versus observation for localized prostate cancer. N Eng J Med 2012; 367: 203213
  • 35
    Wallace K, Fleshner N, Jewett M, Basiuk J, Crook J. Impact of a multi-disciplinary patient education session on accrual to a difficult clinical trial: the Toronto experience with the surgical prostatectomy versus interstitial radiation intervention trial. J Clin Oncol 2006; 24: 41584162
  • 36
    Donovan JL, Lane JA, Peters TJ et al. Development of a complex intervention improved randomization and informed consent in a randomized controlled trial. J Clin Epidemiol 2009; 62: 2936
  • 37
    Greenberg D, Earle C, Fang CH, Eldar-Lissai A, Neumann PJ. When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology. J Natl Cancer Inst 2010; 102: 8288
  • 38
    Kibel AS, Ciezki JP, Klein EA et al. Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era. J Urol 2012; 187: 12591265
  • 39
    Sheets NC, Goldin GH, Meyer AM et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA 2012; 307: 16111620
  • 40
    Nguyen PL, Gu X, Lipsitz SR et al. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol 2011; 29: 15171524
  • 41
    Tewari A, Sooriakumaran P, Bloch DA, Seshadri-Kreaden U, Hebert AE, Wiklund P. Positive surgical margin and perioperative complication rates of primary surgical treatments for prostate cancer: a systematic review and meta-analysis comparing retropubic, laparoscopic, and robotic prostatectomy. Eur Urol 2012; 62: 115
  • 42
    Dall′Era MA, Cooperberg MR, Chan JM et al. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer 2008; 112: 16501659
  • 43
    Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28: 126131
  • 44
    Cooperberg MR, Cowan JE, Hilton JF et al. Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol 2011; 29: 228234
  • 45
    Corcoran AT, Peele PB, Benoit RM. Cost comparison between watchful waiting with active surveillance and active treatment of clinically localized prostate cancer. Urology 2010; 76: 703707